KNSA Q4 2020 Earnings — Kiniksa Pharmaceuticals, Ltd. Revenue & Financial Results | Market Cap Arena

KNSAKiniksa Pharmaceuticals, Ltd.

$3B

Q4 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$53M

Net Income

-$54M

EPS (Diluted)

$-0.79

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$41M

Free Cash Flow

-$41M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$349M

Total Liabilities

$38M

Stockholders' Equity

$312M

Cash & Equivalents

$114M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$53M	-$33M	-62.4%
Net Income	-$54M	-$32M	-68.7%